Loading clinical trials...
Loading clinical trials...
A First in Human Trial to Study Safety and Tolerability of Single Rising Intravitreal Doses (oPen Label, Non-randomized, Uncontrolled) and in Addition the Early Biological Response of mulTiple Intravitreal Doses (Double-masked, RandomIzed, Sham-controlleD) of BI 765128 in Panretinal photocoaGulation (PRP) Treated Diabetic rEtinopathy (DR) Patients With Diabetic Macular Ischemia (DMI) - the PARTRIDGE Study
Conditions
Interventions
BI 765128
Sham comparator
Locations
25
United States
California Retina Consultants
Bakersfield, California, United States
Retinal Consultants Medical Group
Sacramento, California, United States
Bay Area Retina Associates - Walnut Creek
Walnut Creek, California, United States
Cumberland Valley Retina Consultants, PC.
Hagerstown, Maryland, United States
Meridian Clinical Research, LLC
Cincinnati, Ohio, United States
Erie Retina Research, LLC
Erie, Pennsylvania, United States
Start Date
July 30, 2021
Primary Completion Date
August 7, 2023
Completion Date
August 7, 2023
Last Updated
November 21, 2024
NCT07351786
NCT03135327
NCT06782997
NCT06787482
NCT05147701
NCT06892353
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions